Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC By Ogkologos - April 13, 2026 223 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR CAR22 Shows Durable Efficacy After a Single Infusion in Patients with... July 25, 2024 New Device Could “Hear” Stiffening of Extracellular Matrix to Determine Where... April 2, 2020 The right combination for early detection August 4, 2021 Stereotactic Radiosurgery Not Superior in Terms of Pain Response Compared with... April 26, 2023 Load more HOT NEWS Larger NGS Gene Panel Linked to More Clinical Utility Rucaparib Approved as Maintenance Treatment for Some Recurrent Ovarian Cancers For Children with Retinoblastoma, Disparities Seen across the Globe Sustainability a major focus of our 17th year partnering with TK...
